Antiva Biosciences, Inc. announced that it will issue 56,784,090 series D preferred shares at an issue price of $0.5576 per share for the gross proceeds of $31,662,808.584 on October 22, 2021. The shares are convertible, participating, non-redeemable and non-cumulative. The shares carry non-cumulative fixed dividend value of $0.045 per annum per share.

The shares will be convertible in common shares at a fixed conversion price of $0.5576 per share. The company will issue securities pursuant to exemption provided under Regulation D.